Promise of rheumatoid arthritis therapy: From clinical deep remission to drug-free remission

被引:0
|
作者
Hou, Yuke [1 ]
Peng, Yuanhong [2 ]
Jin, Jiayang [1 ]
Li, Zhanguo [1 ]
机构
[1] Peking Univ Peoples Hosp, Dept Rheumatol & Immunol, 11 Xizhimen South St Xicheng Dist, Beijing 100044, Peoples R China
[2] North Sichuan Med Coll, Affiliated Hosp, Dept Rheumatol & Immunol, Nanchong 637000, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
Rheumatoid arthritis; Deep remission; Drug-free remission; Treatment strategy; CliDR; DISEASE-ACTIVITY INDEX; AMERICAN-COLLEGE; VALIDATION; MANAGEMENT; COUNTS; CHINA; CARE;
D O I
10.1016/j.berh.2024.102031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Achieving clinical deep remission (CliDR) in rheumatoid arthritis (RA) is essential to prevent long-term joint damage, enhance patient quality of life, and possibly reduce and discontinue medication eventually. Recent research advances have raised the possibility of achieving deep remission and even drug-free remission. This comprehensive review examines current strategies of RA therapy, concept of deep remission, challenges, and the emerging prospects of drug-free remission. It also reviews the role of different treatments, including conventional diseasemodifying antirheumatic drugs (DMARDs), biologic agents, and targeted synthetic drugs, in the journey from deep remission to drug-free remission. In addition, it emphasizes the importance of patient-centered care, early diagnosis, and individualized treatment approaches in optimizing outcomes for patients with RA.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] ON DRUG AND DRUG-FREE REMISSION BY BASELINE DISEASE DURATION IN THE AVERT TRIAL: ABATACEPT VERSUS METHOTREXATE COMPARISON IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
    Bykerk, V. P.
    Burmester, G. R.
    Combe, B. G.
    Furst, D. E.
    Huizinga, T. W. J.
    Wong, D. A.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 477 - 478
  • [42] ON DRUG AND DRUG-FREE REMISSION BY BASELINE DISEASE DURATION IN THE AVERT TRIAL: ABATACEPT VERSUS METHOTREXATE COMPARISON IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
    Bykerk, Vivian
    Burmester, Gerd
    Combe, Bernard
    Furst, Daniel E.
    Huizinga, Tom
    Wong, Daniel
    Emery, Paul
    RHEUMATOLOGY, 2016, 55 : 97 - 98
  • [43] Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies
    van der Woude, Diane
    Visser, Karen
    Klarenbeek, Naomi B.
    Ronday, H. Karel
    Peeters, Andre J.
    Kerstens, Pit J. S. M.
    Dijkmans, Ben A. C.
    Huizinga, Tom W. J.
    van der Helm-van Mil, Annette H. M.
    Allaart, Cornelia F.
    RHEUMATOLOGY, 2012, 51 (06) : 1120 - 1128
  • [44] Early persistence on therapy impacts drug-free remission: a case-control study in a cohort of Hispanic patients with recent-onset rheumatoid arthritis
    Contreras-Yanez, Irazu
    Arturo Guaracha-Basanez, Guillermo
    Cuevas-Montoya, Maximiliano
    de Jesus Hernandez-Bautista, Jose
    Pascual-Ramos, Virginia
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [45] Prevalence of and Predictive Factors for Sustained Disease-Modifying Antirheumatic Drug-Free Remission in Rheumatoid Arthritis Results From Two Large Early Arthritis Cohorts
    van der Woude, Diane
    Young, Adam
    Jayakumar, Keeranur
    Mertens, Bart J.
    Toes, Rene E. M.
    van der Heijde, Desiree
    Huizinga, Tom W. J.
    van der Helm-van Mil, Annette H. M.
    ARTHRITIS AND RHEUMATISM, 2009, 60 (08): : 2262 - 2271
  • [46] Early persistence on therapy impacts drug-free remission: a case-control study in a cohort of Hispanic patients with recent-onset rheumatoid arthritis
    Irazú Contreras-Yáñez
    Guillermo Arturo Guaracha-Basáñez
    Maximiliano Cuevas-Montoya
    José de Jesús Hernández-Bautista
    Virginia Pascual-Ramos
    Arthritis Research & Therapy, 24
  • [47] Using Circulating Soluble Serum Mediator Profiles to Understand the Mechanisms Driving Disease Flare and Drug-free Remission in Rheumatoid Arthritis
    Anderson, Amy
    Rayner, Fiona
    Degnan, Abbie
    Wilson, Imogen
    Diboll, Julie
    Sim, Jasmine
    Melville, Andrew
    Siebert, Stefan
    McInnes, Iain
    Goodyear, Carl
    Hilkens, Catharien
    Filer, Andrew
    Raza, Karim
    Buckley, Christopher
    Baker, Kenneth
    Pratt, Arthur
    Isaacs, John
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3387 - 3389
  • [48] Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study
    Motomu Hashimoto
    Moritoshi Furu
    Wararu Yamamoto
    Takanori Fujimura
    Ryota Hara
    Masaki Katayama
    Akira Ohnishi
    Kengo Akashi
    Shuzo Yoshida
    Koji Nagai
    Yonsu Son
    Hideki Amuro
    Toru Hirano
    Kosuke Ebina
    Ryuji Uozumi
    Hiromu Ito
    Masao Tanaka
    Koichiro Ohmura
    Takao Fujii
    Tsuneyo Mimori
    Arthritis Research & Therapy, 20
  • [49] Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms
    Ajeganova, S.
    van Steenbergen, H. W.
    van Nies, J. A. B.
    Burgers, L. E.
    Huizinga, T. W. J.
    van der Helm-van Mil, A. H. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (05) : 867 - 873
  • [50] Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study
    Hashimoto, Motomu
    Furu, Moritoshi
    Yamamoto, Wararu
    Fujimura, Takanori
    Hara, Ryota
    Katayama, Masaki
    Ohnishi, Akira
    Akashi, Kengo
    Yoshida, Shuzo
    Nagai, Koji
    Son, Yonsu
    Amuro, Hideki
    Hirano, Toru
    Ebina, Kosuke
    Uozumi, Ryuji
    Ito, Hiromu
    Tanaka, Masao
    Ohmura, Koichiro
    Fujii, Takao
    Mimori, Tsuneyo
    ARTHRITIS RESEARCH & THERAPY, 2018, 20